Schönharting M M, Schade U F
Pharmaceutical Division, Hoechst AG Werk Albert, Wiesbaden, West-Germany.
J Med. 1989;20(1):97-105.
Pentoxifylline (Trental) is a well-known vasoactive drug with proven clinical efficacy in various circulatory disorders. It improves the microcirculation due to its rheologic effects on red blood cells, platelets, and plasmatic components, resulting in a decrease of whole blood viscosity. Surprisingly, it has been found that pentoxifylline will also be of great benefit in different models of animal sepsis, including both gram positive and gram negative bacteria. In these experiments, survival rates are significantly increased in the pentoxifylline group when compared with the controls, which is paralleled by a decrease in germ counts. By different experimental approaches it could be shown that this drug interferes with pathologic granulocyte-endothelium interactions which are closely related to septic symptoms, both downregulating intravasal granulocyte hyperreactivity as well as stimulating antiaggregatory activity of the vessel endothelium. Through this way, beneficial effects of pentoxifylline may be expected in various diseases related to infection, sepsis, and shock which, however, have still to be proven in detailed clinical studies.
己酮可可碱(曲克芦丁)是一种著名的血管活性药物,在各种循环系统疾病中具有已证实的临床疗效。由于其对红细胞、血小板和血浆成分的流变学作用,它可改善微循环,从而降低全血粘度。令人惊讶的是,已发现己酮可可碱在不同的动物败血症模型中也将有很大益处,包括革兰氏阳性菌和革兰氏阴性菌。在这些实验中,与对照组相比,己酮可可碱组的存活率显著提高,同时细菌计数减少。通过不同的实验方法可以表明,这种药物干扰了与败血症症状密切相关的病理性粒细胞 - 内皮细胞相互作用,既下调血管内粒细胞的高反应性,又刺激血管内皮的抗聚集活性。通过这种方式,预计己酮可可碱在与感染、败血症和休克相关的各种疾病中会产生有益作用,然而,这仍有待在详细的临床研究中得到证实。